Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships

Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, which announced this week that they have expanded their drug-development partnership to include work in immunologic and inflammatory diseases.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.